Rhabdomyolysis and statins: a pharmacovigilance comparative study between statins.

Rhabdomyolysis is a serious Adverse Drug Reaction of statins. There are few studies comparing the risk of rhabdomyolysis between the different statins. Using the WHO pharmacovigilance database, Vigibase®, we compared the risk of rhabdomyolysis reporting of seven statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, cerivastatin excluded). All reports of rhabdomyolysis in Vigibase® in adults with statins until 31/12/2022 were included. Results are expressed as Reporting Odds Ratio (ROR, 95% CI). Among 10 657 reports with rhabdomyolysis with statins, simvastatin was the highest risk statin in comparison with others: ROR=2.20 (2.11-2.29). The risk was higher in men, after 74 years and in case of drug interactions.